Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162-170
1 Tel-Aviv University, Tel-Aviv, Israel; Sheba Medical Center, Ramat-Gan, Israel. Electronic address: Ofer.Margalit@sheba.health.gov.il.
2 Department of Quantitative Science Research, Mayo Clinic, Rochester, MN, USA.
3 Tel-Aviv University, Tel-Aviv, Israel; Sheba Medical Center, Ramat-Gan, Israel.
4 Department of Quantitative Science Research, Mayo Clinic, Scottsdale, AZ, USA.
5 Department of Oncology, Division of Medical Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
6 Department of Quantitative Science Research, Mayo Clinic, Rochester, MN, USA; Sorbonne University, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France; Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France.
7 Memorial Sloan Kettering Cancer Centre, New York, NY, USA.
8 Rabin Medical Centre, Petach Tikvah, Israel.
9 Duke Cancer Institute, Duke University, Durham, NC, USA.
10 University of Melbourne, Melbourne, Australia; Austin Health, Heidelberg, Victoria, Australia.
11 David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.
12 Cardiff University and Velindre Cancer Centre, Cardiff, UK.
13 Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France.
14 West Cancer Center, Germantown, TN, USA.
15 Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
16 Department of Medical Oncology, Alfred Health and School of Public Health, Monash University, Melbourne, Australia.
17 Department of Gastrointestinal Oncology, Keck School of Medicine at USC, Los Angeles, CA, USA.